Delayed Puberty

Initiate evaluation when sexual maturation has not become apparent by age 13 years in girls or age 14 years in boys. In boys, document testicular volume and penile length; in girls, document breast development. Record serial height, weight, growth velocity, and Tanner stage because growth deceleration, a stalled pubertal trajectory, or discordance between growth and sexual maturation shifts concern away from uncomplicated constitutional delay. fda+2fda[PDF] BRIEFING BOOK FOR Pediatric Advisory Committee (PAC) - FDApublications aapPUBERTY: NORMAL AND ABNORMAL - AAP Publicationspublications aapDelayed Puberty - AAP Publications

Classify the presentation before ordering broad testing: delayed puberty may reflect transient constitutional delay of growth and puberty (CDGP), functional hypothalamic-pituitary-gonadal suppression, permanent hypogonadotropic hypogonadism, or hypergonadotropic hypogonadism from gonadal insufficiency. This branch point determines whether the next action is observation, investigation and correction of systemic disease, pituitary-hypothalamic evaluation, or gonadal-failure assessment and replacement therapy. BMJ+2BMJDelayed puberty - Symptoms, diagnosis and treatment | BMJ Best Practice USScienceDirectDelayed Puberty - an overviewPubMedA Current Perspective on Delayed Puberty and Its Management

Obtain a left hand and wrist radiograph for bone age, basal LH and FSH, and sex steroids—estradiol in girls and testosterone in boys—alongside growth-velocity assessment. Bone age is typically delayed in CDGP, and common initial assessment includes growth velocity, bone age, LH, FSH, and estradiol or testosterone. publications aap+2publications aapPUBERTY: NORMAL AND ABNORMAL - AAP PublicationsPubMedDelayed puberty versus hypogonadism: a challenge for the pediatrician - PubMedPubMedKallmann Syndrome - StatPearls - NCBI Bookshelf - NIH

Interpret gonadotropins at the first decision point. Elevated LH and FSH indicate primary gonadal failure (hypergonadotropic hypogonadism). Low or normal LH and FSH can occur in CDGP, functional hypothalamic suppression, and congenital or acquired hypogonadotropic hypogonadism; therefore, they should trigger phenotype-based evaluation rather than reassurance. ScienceDirect+2ScienceDirectDelayed Puberty - an overviewPubMedDelayed puberty versus hypogonadism: a challenge for the pediatrician - PMCPubMedCurrent clinical management of constitutional delay of growth and puberty - PubMed

Order targeted studies according to the phenotype. Thyroxine, TSH, and IGF-1 may be appropriate when short stature or impaired growth raises concern for endocrine disease. Dynamic GnRH testing, pelvic ultrasonography to assess uterine and ovarian size, and bone age testing are reserved for selected cases because GnRH-stimulated gonadotropin responses overlap between CDGP and Kallmann syndrome or other isolated hypogonadotropic hypogonadism. PubMed+2PubMedDelayed puberty versus hypogonadism: a challenge for the pediatrician - PMCpublications aapPUBERTY: NORMAL AND ABNORMAL - AAP PublicationsPubMedKallmann Syndrome - StatPearls - NCBI Bookshelf - NIH

Use longitudinal progression as a diagnostic test. CDGP is self-limited, with puberty beginning late but progressing normally; a definitive distinction from permanent hypogonadotropic hypogonadism may require ongoing observation, with lack of puberty by age 18 years supporting permanent hypogonadotropic hypogonadism. BMJ+2BMJDelayed puberty - Symptoms, diagnosis and treatment | BMJ Best Practice USScienceDirectConstitutional delay of puberty versus congenital hypogonadotropic ...PubMedCurrent clinical management of constitutional delay of growth and puberty - PubMed

CDGP is the most frequent cause of delayed puberty and is especially common in boys. The supportive pattern is short stature with delayed skeletal maturation, delayed growth before pubertal onset, a family history of late maturation, and subsequent rapid growth once puberty starts. The management consequence is observation with serial pubertal examination and growth monitoring after excluding organic disease. PubMed+3PubMedDelayed puberty versus hypogonadism: a challenge for the pediatrician - PMCPubMedCurrent clinical management of constitutional delay of growth and puberty - PubMedPubMedDelayed puberty versus hypogonadism: a challenge for the pediatrician - PubMedpublications aapPuberty: Normal and Abnormal (Chapter 185) - AAP Publications

Functional hypogonadotropic hypogonadism is a potentially reversible branch. Celiac disease, inflammatory bowel disease, kidney insufficiency, anorexia nervosa, malnutrition, and excessive exercise can transiently suppress hypothalamic-pituitary-gonadal activation. In this pattern, direct the workup toward the suspected systemic or nutritional driver and reassess pubertal progression after treatment rather than committing prematurely to lifelong hormone replacement. BMJ+2BMJDelayed puberty - Symptoms, diagnosis and treatment | BMJ Best Practice USPubMedCurrent clinical management of constitutional delay of growth and puberty - PubMedPubMedDelayed puberty versus hypogonadism: a challenge for the pediatrician - PubMed

Permanent hypogonadotropic hypogonadism produces low sex steroids with reduced LH and FSH. Congenital cases may first be recognized in adolescence but can have infant clues such as cryptorchidism or micropenis in boys. Kallmann syndrome is a form of congenital hypogonadotropic hypogonadism; differentiation from CDGP remains difficult because hormonal profiles and dynamic testing can overlap. PubMed+2PubMedDelayed puberty versus hypogonadism: a challenge for the pediatrician - PMCPubMedCurrent clinical management of constitutional delay of growth and puberty - PubMedPubMedKallmann Syndrome - StatPearls - NCBI Bookshelf - NIH

Hypergonadotropic hypogonadism reflects gonadal failure: elevated gonadotropins distinguish it from CDGP and central causes. These patients are more likely to need long-term hormone replacement after puberty induction than patients with CDGP, in whom endogenous pubertal activation is expected. BMJ+3BMJDelayed puberty - Symptoms, diagnosis and treatment | BMJ Best Practice USScienceDirectDelayed Puberty - an overviewPubMedCurrent clinical management of constitutional delay of growth and pubertyPubMedPuberty Induction in Adolescent Males: Current Practice

For likely CDGP, observation and reassurance remain appropriate when psychosocial burden is limited. Consider a short course of sex steroids for marked delay or psychosocial maladaptation; treatment in CDGP should be individualized, with a particular role for adolescents older than 14 years with significant distress such as bullying, depression, low self-esteem, or school impairment. BMJ+1BMJDelayed puberty - Symptoms, diagnosis and treatment | BMJ Best Practice USPubMedCurrent clinical management of constitutional delay of growth and puberty

For boys with suspected CDGP, commonly used induction regimens include intramuscular testosterone enanthate 50 mg monthly or oral testosterone undecanoate 40 mg daily for 3 to 6 months. Transdermal options include 1% or 2% testosterone gel providing 10 mg daily or a 5-mg testosterone patch worn for 12 hours daily, although clinical experience is more limited. Reassess after the treatment course for endogenous progression, especially increasing testicular volume; a 3- to 6-month observation window after induction can allow a pubertal "jump start." PubMed+1PubMedA Current Perspective on Delayed Puberty and Its ManagementPubMedTestosterone Use in Adolescent Males: Current Practice and Unmet Needs

One CDGP management approach uses intramuscular testosterone 50 mg monthly, increasing to 100 mg after 6 months when needed; treatment should be prescribed cautiously to avoid undue skeletal maturation acceleration and potential compromise of adult height. In boys receiving a trial, progressive testicular enlargement supports endogenous activation and therefore CDGP rather than permanent central hypogonadism. PubMedPubMedCurrent clinical management of constitutional delay of growth and puberty

For girls with CDGP and selected substantial distress, limited low-dose estradiol—5 to 10 mcg daily for up to 12 months—has been described to induce breast development. In permanent hypo- or hypergonadotropic hypogonadism, use long-term sex-steroid replacement rather than repeated short trials; estrogen with progesterone is used for female hypogonadism, whereas testosterone is the primary treatment for male hypogonadism. PubMed+1PubMedCurrent clinical management of constitutional delay of growth and pubertyPubMedA Current Perspective on Delayed Puberty and Its Management

At each follow-up, document Tanner stage, testicular volume in boys, breast development in girls, height, weight, and growth velocity. In CDGP, linear growth may remain delayed until puberty begins and then accelerates rapidly; failure of this expected clinical progression should reopen the differential for permanent hypogonadism or systemic disease. fda+2fda[PDF] BRIEFING BOOK FOR Pediatric Advisory Committee (PAC) - FDAPubMedCurrent clinical management of constitutional delay of growth and puberty - PubMedPubMedDelayed puberty versus hypogonadism: a challenge for the pediatrician - PubMed

After a 3- to 6-month induction course for presumed CDGP, allow a 3- to 6-month observation interval to detect autonomous pubertal progression. In boys, a rise in testicular volume to approximately 6 to 8 mL indicates significant hypothalamic-pituitary-gonadal axis activation; absent progression after limited trials should prompt reassessment for permanent hypogonadism and planning for long-term replacement. PubMed+1PubMedA Current Perspective on Delayed Puberty and Its ManagementPubMedTestosterone Use in Adolescent Males: Current Practice and Unmet Needs

Continue endocrine follow-up through completion of pubertal development in permanent hypo- or hypergonadotropic hypogonadism. These adolescents usually require ongoing hormone replacement after induction, whereas CDGP treatment can be discontinued once endogenous puberty is established. BMJ+2BMJDelayed puberty - Symptoms, diagnosis and treatment | BMJ Best Practice USPubMedCurrent clinical management of constitutional delay of growth and pubertyPubMedA Current Perspective on Delayed Puberty and Its Management